fingolimod hydrochloride has been researched along with Autoimmune Diseases in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (46.88) | 29.6817 |
| 2010's | 15 (46.88) | 24.3611 |
| 2020's | 2 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Shamma, H; Barden, J; Buzard, D; Edwards, J; Espinola, S; Fu, L; Gao, Y; Gatlin, J; Han, S; Jones, RM; Kawasaki, A; Le, M; Liu, L; Lopez, L; Moody, J; Sage, C; Schrader, T; Solomon, M; Thatte, J; Thoresen, L; Xing, C | 1 |
| Bravo, GÁ; Casadevall, MP; Cedeño, RR; Ramió-Torrentà, L | 1 |
| Chitnis, T; Gonzalez-Martinez, A; Healy, BC; Lokhande, H; Patel, R; Paul, A; Polgar-Turcsanyi, M; Saxena, S; Weiner, HL | 1 |
| Kusnecov, AW | 1 |
| Camp, SM; Garcia, JGN; Marciniak, A; Polt, R | 1 |
| Bieber, K; Gupta, Y; Kalies, K; Ludwig, RJ; Mousavi, S; Sadik, CD; Sezin, T; Thieme, M; Wannick, M; Zillikens, D | 1 |
| Hla, T; Proia, RL | 1 |
| Brand, DD; Hasty, KA; Miller, DC; Rosloniec, EF; Whittington, KB | 1 |
| Guerrero, M; Roberts, E; Urbano, M | 1 |
| Han, MH; Tsai, HC | 1 |
| Copland, DA; Dick, AD; Nicholson, LB; Raveney, BJ | 1 |
| Chiba, K | 3 |
| Arslanian, C; Belfort, R; Bueno, V; Commodaro, AG; Lopes, CT; Peron, JP; Rizzo, LV | 1 |
| Gräler, MH | 1 |
| Belfort, R; Bueno, V; Commodaro, AG; Rizzo, LV | 1 |
| Schluesener, HJ; Zhang, ZY; Zug, C | 1 |
| Brinkmann, V; Hla, T | 1 |
| Anderson, K; Brinkmann, V; Copland, DA; Dick, AD; Liu, J; Nicholson, LB; Schewitz-Bowers, LP | 1 |
| Cocco, G | 1 |
| Brinkmann, V; Lynch, KR | 1 |
| Brinkmann, V | 1 |
| Goto, R; Ichimaru, N; Kangawa, K; Kawano, Y; Moriyama, T; Nakahama, H; Okuyama, A; Sada, M; Shi, Y; Takahara, S; Yazawa, K; Yoshihara, F | 1 |
| Don, AS; Martinez-Lamenca, C; Proia, RL; Roberts, E; Rosen, H; Webb, WR | 1 |
| Chiba, K; Kataoka, H | 1 |
| Hikita, N; Ikeda, E; Kurose, S; Mochizuki, M; Tokiwa, M | 1 |
| Isobe, M; Kitabayashi, H; Sekiguchi, M; Suzuki, J; Watanabe, N; Yazaki, Y | 1 |
| Chiba, K; Kobayakawa, T | 1 |
| Brinkmann, V; Hengartner, H; Ochsenbein, AF; Odermatt, B; Pinschewer, DD; Zinkernagel, RM | 1 |
| Brinkmann, V; Chen, S; Feng, L; Pinschewer, DD | 1 |
| Brinkmann, V; Deleo, J; Fu, F; Hoover, J; Hopf, C; Hu, S; Lake, P; Li, S; Shi, VC; Wang, S | 1 |
16 review(s) available for fingolimod hydrochloride and Autoimmune Diseases
| Article | Year |
|---|---|
Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
Topics: Autoimmune Diseases; Fingolimod Hydrochloride; Humans; Lysophospholipids; Multiple Sclerosis; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2022 |
An update on sphingosine-1-phosphate receptor 1 modulators.
Topics: Autoimmune Diseases; Biological Availability; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Oxadiazoles; Receptors, Lysosphingolipid; Sphingolipids | 2018 |
Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.
Topics: Acute Lung Injury; Anemia, Sickle Cell; Animals; Autoimmune Diseases; Cardiovascular Diseases; Cell Physiological Phenomena; Disease Models, Animal; Fingolimod Hydrochloride; Hematopoietic Stem Cell Mobilization; Humans; Influenza, Human; Lysophospholipids; Membrane Lipids; Mice; Multiple Sclerosis; Neoplasms; Neovascularization, Physiologic; Neurogenesis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine | 2015 |
Sphingosine 1-phosphate receptor 1 agonists: a patent review (2013-2015).
Topics: Animals; Autoimmune Diseases; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Lysophospholipids; Multiple Sclerosis, Relapsing-Remitting; Patents as Topic; Receptors, Lysosphingolipid; Sphingosine | 2016 |
Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.
Topics: Animals; Autoimmune Diseases; Fingolimod Hydrochloride; Humans; Inflammation; Lymphocytes; Lysophospholipids; Molecular Targeted Therapy; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2016 |
[A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Topics: Animals; Autoimmune Diseases; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine | 2009 |
[New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Topics: Animals; Autoimmune Diseases; Clinical Trials as Topic; Encephalomyelitis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2009 |
Targeting sphingosine 1-phosphate (S1P) levels and S1P receptor functions for therapeutic immune interventions.
Topics: Autoimmune Diseases; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Lysophospholipids; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2010 |
Autoimmune uveitis: the associated proinflammatory molecules and the search for immunoregulation.
Topics: Animals; Autoimmune Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunomodulation; Inflammation Mediators; Propylene Glycols; Sphingosine; Uveitis | 2011 |
Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Topics: Animals; Autoimmune Diseases; Cardiovascular System; Central Nervous System; Fingolimod Hydrochloride; Humans; Immune System; Immunosuppressive Agents; Lymph Nodes; Lysophospholipids; Models, Biological; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2011 |
FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity.
Topics: Animals; Autoimmune Diseases; Bone Marrow Transplantation; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Islets of Langerhans Transplantation; Lymph Nodes; Peyer's Patches; Propylene Glycols; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine | 2002 |
FTY720: mechanism of action and potential benefit in organ transplantation.
Topics: Animals; Autoimmune Diseases; Clinical Trials as Topic; Endothelium, Vascular; Fingolimod Hydrochloride; Humans; Immune System; Immunosuppressive Agents; Organ Transplantation; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Transplantation Immunology | 2004 |
FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Topics: Animals; Autoimmune Diseases; Calcineurin Inhibitors; Clinical Trials as Topic; Disease Models, Animal; Drug Synergism; Fingolimod Hydrochloride; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymph Nodes; Lymphocytes; Peyer's Patches; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Spleen; T-Lymphocytes; Thymus Gland | 2005 |
[Therapeutic effect of S1P receptor modifying drugs for autoimmune diseases].
Topics: Animals; Autoimmune Diseases; Clinical Trials, Phase II as Topic; Disease Models, Animal; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2008 |
[Immunosuppressive agent FTY720].
Topics: Acute Disease; Animals; Autoimmune Diseases; Cyclosporine; Drug Design; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Propylene Glycols; Sphingosine; Transplantation, Homologous | 2000 |
FTY720: altered lymphocyte traffic results in allograft protection.
Topics: Animals; Autoimmune Diseases; Cell Movement; Chemokines; Clinical Trials as Topic; Cyclosporine; Diabetes Mellitus, Type 1; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Humans; Immunologic Memory; Immunosuppressive Agents; Inflammation; Islets of Langerhans Transplantation; Lymphocyte Activation; Lymphocytes; Models, Animal; Propylene Glycols; Safety; Sphingosine; Transplantation, Homologous | 2001 |
16 other study(ies) available for fingolimod hydrochloride and Autoimmune Diseases
| Article | Year |
|---|---|
Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P₁ agonists.
Topics: Animals; Autoimmune Diseases; Butyrates; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Haplorhini; High-Throughput Screening Assays; Humans; Immunosuppressive Agents; Indoles; Lymphocytes; Male; Mice; Mice, Inbred BALB C; Nerve Tissue Proteins; Oxadiazoles; Rats; Rats, Sprague-Dawley; RNA-Binding Proteins; Structure-Activity Relationship; Substrate Specificity | 2011 |
miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod.
Topics: Adolescent; Autoimmune Diseases; Biomarkers; Fingolimod Hydrochloride; Humans; MicroRNAs; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2023 |
From the head of a caterpillar: A possible treatment for neuropsychiatric sequelae of autoimmune disease.
Topics: Animals; Autoimmune Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Lupus Erythematosus, Systemic; Mice | 2018 |
The Sphingosine-1-Phosphate Receptor Modulator Fingolimod Aggravates Murine Epidermolysis Bullosa Acquisita.
Topics: Animals; Autoantibodies; Autoimmune Diseases; Cells, Cultured; Collagen Type VII; Disease Models, Animal; Epidermolysis Bullosa Acquisita; Fingolimod Hydrochloride; Forkhead Transcription Factors; Humans; Inflammation; Interleukin-10; Intraepithelial Lymphocytes; Mice; Neutrophils; Skin; Sphingosine-1-Phosphate Receptors; T-Lymphocytes, Regulatory | 2019 |
The CII-specific autoimmune T-cell response develops in the presence of FTY720 but is regulated by enhanced Treg cells that inhibit the development of autoimmune arthritis.
Topics: Animals; Arthritis, Experimental; Autoimmune Diseases; Autoimmunity; Collagen Type II; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Transgenic; T-Lymphocytes, Regulatory | 2016 |
Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease.
Topics: Administration, Oral; Animals; Autoimmune Diseases; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Emergency Treatment; Female; Fingolimod Hydrochloride; Immunohistochemistry; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Propylene Glycols; Random Allocation; Reference Values; Retinitis; Sensitivity and Specificity; Sphingosine; Treatment Outcome; Uveitis | 2008 |
Evaluation of experimental autoimmune uveitis in mice treated with FTY720.
Topics: Animals; Autoimmune Diseases; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cell Movement; Cytokines; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Eye Proteins; Fingolimod Hydrochloride; Flow Cytometry; Immunoglobulin G; Immunosuppressive Agents; Interleukin-2 Receptor alpha Subunit; Intubation, Gastrointestinal; Lymph Nodes; Mice; Peptide Fragments; Propylene Glycols; Retinol-Binding Proteins; Sphingosine; T-Lymphocytes, Regulatory; Uveitis, Posterior | 2010 |
Sphingosine 1-phosphate receptor modulator FTY720 suppresses rat experimental autoimmune prostatitis.
Topics: Animals; Autoimmune Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Immunohistochemistry; Immunosuppressive Agents; Male; Propylene Glycols; Prostatitis; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Specific Pathogen-Free Organisms; Sphingosine | 2011 |
Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier.
Topics: Animals; Apoptosis; Autoimmune Diseases; Blood-Retinal Barrier; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Microvessels; Permeability; Propylene Glycols; Retinitis; Sphingosine; Uveitis | 2012 |
A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart?
Topics: Arthritis, Psoriatic; Atrial Fibrillation; Autoimmune Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Factor V; Fingolimod Hydrochloride; Heart; Heart Diseases; Heart Failure; Humans; Hypertension; Immunosuppressive Agents; Male; Middle Aged; Mitral Valve Insufficiency; Multiple Sclerosis; Mutation; Myocardium; Propylene Glycols; Pyrazoles; Sjogren's Syndrome; Sphingosine; Sulfonamides | 2012 |
A novel immunosuppressant FTY720 ameliorates proteinuria and alterations of intrarenal adrenomedullin in rats with autoimmune glomerulonephritis.
Topics: Adrenomedullin; Animals; Autoimmune Diseases; Blood Chemical Analysis; Fingolimod Hydrochloride; Glomerulonephritis; Humans; Immunosuppressive Agents; Kidney; Male; Mercuric Chloride; Peptides; Propylene Glycols; Proteinuria; Radioimmunoassay; Random Allocation; Rats; Sphingosine; Statistics as Topic; Urine | 2005 |
Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
Topics: Animals; Apoptosis; Autoimmune Diseases; bcl-2-Associated X Protein; Calcium Signaling; Caspases; Cell Membrane Permeability; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Fingolimod Hydrochloride; HeLa Cells; Humans; Immunosuppressive Agents; Jurkat Cells; Lymphoproliferative Disorders; Mice; Mice, Knockout; Mitochondria; Mutagenesis; Organ Specificity; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Protein Transport; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine; Spleen; Thymus Gland | 2007 |
Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats.
Topics: Animals; Antibodies; Arrestin; Autoimmune Diseases; Blood Cell Count; Body Weight; Chi-Square Distribution; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Propylene Glycols; Rats; Rats, Inbred Lew; Retinitis; Sphingosine; Statistics, Nonparametric; T-Lymphocytes; Uveitis | 2000 |
FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes.
Topics: Analysis of Variance; Animals; Autoimmune Diseases; Body Weight; Fingolimod Hydrochloride; Immunosuppressive Agents; Injections, Intraperitoneal; Lymphocyte Count; Lymphocytes; Male; Myocarditis; Organ Size; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; Tacrolimus | 2000 |
FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.
Topics: Animals; Antibodies, Viral; Autoimmune Diseases; Cell Movement; Cytotoxicity, Immunologic; Diabetes Mellitus, Experimental; Edema; Fingolimod Hydrochloride; Hypersensitivity, Delayed; Immunologic Memory; Immunosuppressive Agents; Lymphocyte Activation; Lymphocyte Count; Lymphocytic choriomeningitis virus; Lymphopenia; Mice; Mice, Inbred C57BL; Mice, Transgenic; Propylene Glycols; Sphingosine; T-Lymphocytes, Cytotoxic | 2000 |
Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720.
Topics: Animals; Autoimmune Diseases; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred CBA; Mice, Inbred NOD; Propylene Glycols; Sphingosine; Time Factors | 2002 |